Skip to content

Effects of Cord Blood 25-hydroxy-vitamin D Level on Early Neonatal Morbidities

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02147327
Enrollment
120
Registered
2014-05-26
Start date
2013-10-31
Completion date
2014-05-31
Last updated
2014-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal Hypocalcemia, Neonatal Sepsis

Keywords

vitamin D, cord blood, neonatal sepsis, neonatal morbidity

Brief summary

Cholecalciferol (vitamin D3) is a prohormone and its active form is 1,25 dihydroxycholecalciferol. This hormone has effect on both calcium, phosphorus and bone metabolism and also bone morrow, muscle, heart and immune system. For a long time, maternal low vitamin D level is a well known problem for our country and the level was reported as \<10 ng/ml for 46-80% of mothers.The most prominent risk factor was determined as low socioeconomic status. Therefore, the level of 25-hydroxy-vitamin D is supposed to be in relation with several neonatal morbidities and maternal complications of pregnancy.

Interventions

None listed

Sponsors

Zekai Tahir Burak Women's Health Research and Education Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 30 Minutes
Healthy volunteers
No

Inclusion criteria

* Term or preterm newborns which are hospitalized in the Neonatal Intensive Care Unit of our hospital

Exclusion criteria

* Preterm babies born before the 24. gestational week * Babies with complex cardiac anomalies and/or dysmorphic features

Design outcomes

Primary

MeasureTime frame
maternal complications of pregnancyfrom the beginning of gestation until birth process
sepsis3 months but patients will be followed until discharge
feeding intolerance3 months but patients will be followed until discharge
hypocalcemia3 months but patients will be followed until discharge
bronchopulmonary dysplasia3 months but patients will be followed until discharge
patent ductus arteriosis3 months but patients will be followed until discharge
retinopathy of prematurity3 months but patients will be followed until discharge

Secondary

MeasureTime frame
rachitism4 months but patients will be followed until discharge

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026